Speciality Pharma

The clinical validation of next-generation oncology therapeutics brings hope to difficult-to-treat cancers. Sourcing medical directors specialised in solid tumours is critical.

The shift from injectable to oral GLP-1 formulations is transforming the metabolic sector. Discover the commercialisation capabilities required to lead these multi-billion pound launches.

Deploying molecular screening systems in low-resource environments requires operational directors with deep international supply chain and NGO partnerships experience.

Partnering late-stage molecules requires business development executives with a proven track record of structure-maximising deal negotiations.

Launching a therapy in a newly defined disease area presents unique market-access challenges. We analyse the commercial competencies required to build new treatment pathways.

The clinical success of Actinium-225 conjugates has sparked a race for specialised production capacity. We explore the recruitment of operational leaders who speak the language of nuclear medicine.